Arbutus Biopharma (ABUS) Competitors $4.25 -0.17 (-3.85%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$4.24 -0.01 (-0.35%) As of 09/19/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABUS vs. MLTX, KYMR, CRNX, AMRX, APLS, HCM, TLX, SRRK, RARE, and CNTAShould you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include MoonLake Immunotherapeutics (MLTX), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), AMNEAL PHARMACEUTICALS (AMRX), Apellis Pharmaceuticals (APLS), HUTCHMED (HCM), Telix Pharmaceuticals (TLX), Scholar Rock (SRRK), Ultragenyx Pharmaceutical (RARE), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry. Arbutus Biopharma vs. Its Competitors MoonLake Immunotherapeutics Kymera Therapeutics Crinetics Pharmaceuticals AMNEAL PHARMACEUTICALS Apellis Pharmaceuticals HUTCHMED Telix Pharmaceuticals Scholar Rock Ultragenyx Pharmaceutical Centessa Pharmaceuticals Arbutus Biopharma (NASDAQ:ABUS) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment. Is ABUS or MLTX more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -352.24%. MoonLake Immunotherapeutics' return on equity of -40.98% beat Arbutus Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Arbutus Biopharma-352.24% -59.28% -44.11% MoonLake Immunotherapeutics N/A -40.98%-35.81% Which has more risk & volatility, ABUS or MLTX? Arbutus Biopharma has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Do analysts recommend ABUS or MLTX? Arbutus Biopharma presently has a consensus target price of $5.00, indicating a potential upside of 17.65%. MoonLake Immunotherapeutics has a consensus target price of $74.43, indicating a potential upside of 38.39%. Given MoonLake Immunotherapeutics' higher probable upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Arbutus Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00MoonLake Immunotherapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Does the media favor ABUS or MLTX? In the previous week, Arbutus Biopharma and Arbutus Biopharma both had 5 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 1.12 beat Arbutus Biopharma's score of 0.57 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in ABUS or MLTX? 43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 20.3% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings and valuation, ABUS or MLTX? Arbutus Biopharma has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArbutus Biopharma$6.17M132.05-$69.92M-$0.29-14.66MoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.78-19.35 SummaryMoonLake Immunotherapeutics beats Arbutus Biopharma on 8 of the 14 factors compared between the two stocks. Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABUS vs. The Competition Export to ExcelMetricArbutus BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$814.72M$3.15B$5.79B$10.47BDividend YieldN/A2.35%5.61%4.61%P/E Ratio-14.6620.9180.5026.81Price / Sales132.05415.21519.29119.31Price / CashN/A46.4637.6661.43Price / Book8.339.6015.756.39Net Income-$69.92M-$53.22M$3.30B$271.80M7 Day Performance-4.71%3.11%5.37%3.49%1 Month Performance21.78%7.56%8.10%9.90%1 Year Performance5.72%11.15%81.37%28.62% Arbutus Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABUSArbutus Biopharma2.117 of 5 stars$4.25-3.8%$5.00+17.6%+2.7%$814.72M$6.17M-14.6690Positive NewsMLTXMoonLake Immunotherapeutics2.4725 of 5 stars$53.27+1.2%$74.43+39.7%+0.1%$3.38BN/A0.002KYMRKymera Therapeutics2.1819 of 5 stars$47.28+0.6%$58.76+24.3%+0.2%$3.36B$47.07M0.00170Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionCRNXCrinetics Pharmaceuticals3.6092 of 5 stars$33.77-0.7%$68.86+103.9%-37.1%$3.20B$1.04M-8.22210Positive NewsAMRXAMNEAL PHARMACEUTICALS3.8135 of 5 stars$9.79-2.1%$11.60+18.5%+11.4%$3.14B$2.79B14.938,100Positive NewsAnalyst ForecastAPLSApellis Pharmaceuticals4.1202 of 5 stars$24.39-1.9%$34.12+39.9%-37.4%$3.14B$781.37M0.00770Trending NewsInsider TradeAnalyst RevisionHCMHUTCHMED2.6425 of 5 stars$17.54-2.2%$28.00+59.6%+1.4%$3.13B$630.20M0.001,811TLXTelix Pharmaceuticals3.7991 of 5 stars$9.51+3.3%$21.33+124.3%N/A$3.12B$516.72M0.00N/AAnalyst ForecastSRRKScholar Rock4.3443 of 5 stars$33.67+6.3%$46.33+37.6%+262.4%$3.04B$33.19M-11.57140News CoverageAnalyst ForecastInsider TradeAnalyst RevisionRAREUltragenyx Pharmaceutical4.4638 of 5 stars$29.00-4.3%$81.50+181.0%-52.1%$2.92B$560.23M-5.241,294Positive NewsCNTACentessa Pharmaceuticals3.2064 of 5 stars$22.02+1.0%$32.70+48.5%+43.8%$2.92B$6.85M0.00200Insider Trade Related Companies and Tools Related Companies MLTX Alternatives KYMR Alternatives CRNX Alternatives AMRX Alternatives APLS Alternatives HCM Alternatives TLX Alternatives SRRK Alternatives RARE Alternatives CNTA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABUS) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABUS Stock Alerts